ASCENT is a multicenter, open-label, randomized, phase 3 study in patients with metastatic triple negative breast cancer (TNBC) refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. Learn about eligibility requirements for the ASCENT trial.
Patients meeting eligibility will be randomized 1:1 to receive either sacituzumab govitecan or treatment of physician choice (TPC), which needs to be selected prior to randomization. Learn more about the ASCENT trial design.
Outcome measures include: progression-free survival, overall survival, objective response rate, duration of response, and time to onset of response. See full information about outcome measures.
Find a list of ASCENT Trial participating centers here.
For questions or more information about the ASCENT Trial, please contact us.
Patients meeting eligibility will be randomized 1:1 to receive either sacituzumab govitecan or treatment of physician choice (TPC), which needs to be selected prior to randomization from 1 of the 4 allowed regimens. Subjects will be treated until progression, unacceptable toxicity, study withdrawal, or death, whichever comes first.
Patients with metastatic TNBC who are refractory/relapsed after 2 or more prior standard-of-care chemotherapies, including taxanes, for advanced disease. See Eligibility for the complete list of inclusion and exclusion criteria.
10 mg/kg on Days 1 and 8 of 21-day cycles
1 of the following 4 TPC regimens (no combinations are permitted):
Primary outcome measure
Secondary outcome measures
Key entry criteria